ANAPTYSBIO, INC — Director's Dealing 2021

Dec 23, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANAPTYSBIO, INC (ANAB)
CIK: 0001370053
Period of Report: 2021-12-20

Reporting Person: Suria Hamza (Director, President, CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-20	Common Stock	M	36645	$1.12	Acquired	105245	Direct
2021-12-20	Common Stock	S	11915	$34.8935	Disposed	93330	Direct
2021-12-20	Common Stock	S	19208	$35.7547	Disposed	74122	Direct
2021-12-20	Common Stock	S	5522	$36.4046	Disposed	68600	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-20	Employee Stock Option (Right to Buy)	$1.12	M	36645	Disposed	2022-01-31	Common Stock (36645)	Direct

Footnotes

F1: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.25 to $35.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.26 to $36.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.26 to $36.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F5: The stock option grant was issued on February 1, 2012, is fully vested and exercisable until its expiration date of January 31, 2022.

F6: In addition to the remaining options to purchase 0 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,118,893 shares of common stock, which options vest according to their terms, and (ii) 68,600 shares of common stock held directly.